REPLIGEN CORP — Director's Dealing 2022

Oct 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2022-10-07

Reporting Person: Snodgres Jon (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-07	Common Stock	M	466	$59.52	Acquired	34972	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-07	Stock Option (Right to Buy)	$59.52	M	466	Acquired	2029-02-28	Common Stock (466)	Direct

Footnotes

F1: Exercise of options was effected pursuant to a 10(b)5-1 trading plan adopted on September 6, 2022.

F2: This option is fully vested and exercisable.